Skip to main content
Auro Laboratories Ltd. logo

Auro Laboratories Ltd. — Investor Relations & Filings

Ticker · 530233 ISIN · INE292C01011 LEI · 335800X1NEIR7EEPQC63 BSE.NS Manufacturing
Open in API
Filings indexed 6 across all filing types
Latest filing 2026-05-29 Regulatory Filings
Country IN India
Listing BSE.NS 530233

About Auro Laboratories Ltd.

http://www.aurolabs.com

Auro Laboratories Ltd. specializes in the manufacturing of Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates. The company primarily focuses on the production of anti-diabetic drugs, with Metformin Hydrochloride being its flagship product. Its manufacturing facilities are compliant with World Health Organization Good Manufacturing Practices (WHO-GMP) and ISO standards, ensuring high-quality output for global markets. Auro Laboratories maintains a strong emphasis on research and development to optimize production processes and expand its product portfolio, which includes various specialty chemicals and therapeutic agents. The company provides cost-effective pharmaceutical solutions through integrated manufacturing capabilities and rigorous quality assurance protocols.

Recent filings

Filing Released Lang Actions
Enclosed herewith Annual Secretarial Compliance Report for the Year Ended March 31, 2026.
Regulatory Filings Classification · 93% confidence The document is an Annual Secretarial Compliance Report issued under Regulation 24A of SEBI (LODR) Regulations, 2015, certifying the company’s compliance with various listing obligations. It is not an Annual Report, financial statement, or presentation, nor is it a proxy or earnings release. Instead, it is a statutory compliance certificate submitted to the stock exchange. Such compliance certificates fall under general regulatory filings rather than a specific financial report category. Therefore, it is classified as a Regulatory Filing (RNS).
2026-05-29 English
Enclosed herewith appointment of Chief Financial Officer, Tax Auditor, Internal Auditor and Reappointment of Cost Auditor.
Regulatory Filings Classification · 93% confidence The document is an outcome of a Board meeting under SEBI LODR Regulation 30 & 33, filed with the stock exchange. It contains multiple compliance disclosures: appointments of key managerial personnel and auditors, and the audited financial results for the quarter and year ended March 31, 2026. While it includes the financial statements, this is part of a regulatory board‐meeting outcome notice rather than the full Annual Report or standalone Interim Report. It does not fit purely into management changes (MANG) or an Interim/Quarterly Report (IR) because it is a composite regulatory announcement with attachments. Therefore it falls into the general “Regulatory Filings” category (RNS).
2026-05-29 English
Enclosed herewith Financial Results for the year ended March 31, 2026
Earnings Release Classification · 80% confidence The document is a regulatory exchange filing under SEBI LODR (Regulation 30 & 33) entitled “Outcome of the Meeting of Board of Directors,” dated May 29, 2026. It announces (a) key Board approvals (appointment of CFO, Tax/Internal/Cost Auditors) and (b) the audited financial results for the quarter and year ended March 31, 2026, including detailed income statement line items, statement of assets & liabilities, cash flow statement and auditor’s report. This constitutes the company’s official earnings announcement rather than a full annual report or mere notice of publication. It is not purely a management change notice (MANG) nor just a brief publication announcement (RPA). It is the initial quarterly/annual results disclosure – an Earnings Release under our taxonomy. FY 2026
2026-05-29 English
Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we wish to inform you that the Board of Directors of the Company ....
Regulatory Filings Classification · 85% confidence The document is an official SEBI LODR announcement at BSE covering the outcome of the Board meeting, including appointments of key managerial personnel and auditors and the approval of audited financial results for the quarter and year ended March 31, 2026. It is not a standalone 10-K or full Annual Report, nor is it a proxy or governance charter. It is a regulatory compliance announcement under SEBI regulations and does not qualify as an earnings release (ER) or interim report (IR) itself but rather a filing to the exchange. Therefore, it falls under Regulatory Filings (RNS).
2026-05-29 English
Auro Laboratories Limited has submitted the Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 for Resignation of Mr. Kuntal Pancholi as the Chief Financial Officer & Key Managerial ....
Board/Management Information Classification · 87% confidence The document is a regulatory disclosure under SEBI (LODR) Regulation 30 announcing the resignation of the Chief Financial Officer and Key Managerial Personnel. This is an official announcement of a senior management change, fitting the Board/Management Information category.
2026-05-28 English
Auro Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve Audited Financial Results ....
Regulatory Filings Classification · 85% confidence The document is a compliance letter under Regulation 29 of the SEBI Listing Regulations notifying the stock exchange of an upcoming Board meeting to consider audited financial results. It does not contain the results themselves, nor is it a proxy statement or dividend notice. It is a general regulatory announcement, so it falls under the fallback category of Regulatory Filings (RNS).
2026-05-25 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.